- Home
- BHF vs HCM Comparison
BHF vs HCM Comparison
Compare BHF & HCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BHF
- HCM
- Stock Information
- Founded
- BHF 2016
- HCM 2000
- Country
- BHF United States
- HCM Hong Kong
- Employees
- BHF N/A
- HCM N/A
- Industry
- BHF Life Insurance
- HCM Biotechnology: Pharmaceutical Preparations
- Sector
- BHF Finance
- HCM Health Care
- Exchange
- BHF Nasdaq
- HCM Nasdaq
- Market Cap
- BHF 2.8B
- HCM 2.5B
- IPO Year
- BHF N/A
- HCM N/A
- Fundamental
- Price
- BHF $59.81
- HCM $13.89
- Analyst Decision
- BHF Hold
- HCM Hold
- Analyst Count
- BHF 10
- HCM 1
- Target Price
- BHF $57.90
- HCM $19.00
- AVG Volume (30 Days)
- BHF 846.7K
- HCM 62.8K
- Earning Date
- BHF 05-08-2025
- HCM 03-19-2025
- Dividend Yield
- BHF N/A
- HCM N/A
- EPS Growth
- BHF N/A
- HCM N/A
- EPS
- BHF 8.45
- HCM 0.04
- Revenue
- BHF $8,610,000,000.00
- HCM $630,201,000.00
- Revenue This Year
- BHF $42.62
- HCM $14.86
- Revenue Next Year
- BHF $2.05
- HCM $19.54
- P/E Ratio
- BHF $7.08
- HCM $63.20
- Revenue Growth
- BHF 165.09
- HCM N/A
- 52 Week Low
- BHF $40.00
- HCM $11.51
- 52 Week High
- BHF $64.12
- HCM $21.50
- Technical
- Relative Strength Index (RSI)
- BHF 55.86
- HCM 50.07
- Support Level
- BHF $58.18
- HCM $13.13
- Resistance Level
- BHF $60.94
- HCM $13.66
- Average True Range (ATR)
- BHF 1.81
- HCM 0.36
- MACD
- BHF -0.19
- HCM 0.05
- Stochastic Oscillator
- BHF 48.37
- HCM 81.25
About BHF Brighthouse Financial Inc.
Brighthouse Financial Inc is a United States-based provider of annuity products and life insurance through independent distribution channels and marketing arrangements with distribution partners. Its segments are Annuities, Life, Run-off and Corporate and Other. It derives a majority of the revenue from the Annuities segment which includes variable, fixed, index-linked, and income annuities. The life segment includes variable, term, universal, and whole life policies.
About HCM HUTCHMED (China) Limited
HUTCHMED (China) Ltd is an innovative biopharmaceutical company engaged in the discovery, global development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The company operates in two reportable segments Oncology/Immunology, and Other Ventures.